Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Sarcoidosis from an immunological perspective - experience-based diagnosis and treatment with targeted therapies].

Created on 01 Sep 2026

Authors

Aresh Farokhnia, Christian Friedrich Clarenbach, Lukas Frischknecht, Jakob Nilsson

Published in

Therapeutische Umschau. Revue therapeutique. Volume 83. Issue 4. Pages 126-132.

Abstract

This review summarizes the immunologic approach to systemic sarcoidosis and presents the use of novel, targeted therapies such as TNF-alpha inhibitors and Janus kinase (JAK) inhibitors. Sarcoidosis is a granulomatous multisystem disease with diverse clinical manifestations that requires differentiated diagnostic and therapeutic strategies. The recommendations presented here are based on extensive clinical experience and expert opinion from the certified sarcoidosis center of excellence at University Hospital Zurich. The article provides an overview of immunopathogenesis, immunoserologic and imaging diagnostic pathways, as well as an evaluation of established and novel therapeutic concepts. Practical guidance for the use of TNF-alpha and JAK inhibitors, for adverse effect management, and for therapy escalation is presented. A focus is also placed on the indication for consultation in difficult cases to support primary care physicians in the effective and individually tailored care of patients with systemic sarcoidosis.

PMID:
42678144
Bibliographic data and abstract were imported from PubMed on 01 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement